Biohaven Ltd. (BHVN) — SEC Filings
Biohaven Ltd. (BHVN) — 43 SEC filings. Latest: 4 (May 1, 2026). Includes 20 8-K, 7 4, 7 SC 13G/A.
View Biohaven Ltd. on SEC EDGAR
Overview
Biohaven Ltd. (BHVN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on May 1, 2026: On April 30, 2026, Michael Thomas Heffernan reported a change in beneficial ownership of securities for Biohaven Ltd. The filing, dated April 28, 2026, details transactions related to his holdings.
Sentiment Summary
Across 43 filings, the sentiment breakdown is: 1 bullish, 41 neutral, 1 mixed. The dominant filing sentiment for Biohaven Ltd. is neutral.
Filing Type Overview
Biohaven Ltd. (BHVN) has filed 7 4, 20 8-K, 4 10-Q, 2 DEF 14A, 2 10-K, 7 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (43)
Risk Profile
Risk Assessment: Of BHVN's 29 recent filings, 1 were flagged as high-risk, 2 as medium-risk, and 26 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$173.443M |
| EPS | -$1.64 |
| Cash Position | $184.847M |
| Total Assets | $409.123M |
| Total Debt | $268.270M |
Key Executives
- Michael Thomas Heffernan
- Irina Antonijevic
- John W. Childs
Industry Context
Biohaven operates in the highly competitive biopharmaceutical sector, focusing on immunology, neuroscience, and oncology. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Success hinges on innovation, clinical trial outcomes, and the ability to secure funding for pipeline advancement.
Top Tags
8-K (6) · disclosure (6) · regulatory-filing (5) · filing (4) · 8-k (4) · ownership-change (3) · financials (3) · financial-reporting (3) · sec-filing (3) · 10-Q (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $173.443M | Increased from $160.304M in Q3 2024, an 8.2% increase. |
| Net Loss (YTD Sep 2025) | $593.267M | Decreased from $659.579M in YTD Sep 2024, a 10.1% reduction. |
| Research and Development Expenses (Q3 2025) | $141.169M | Decreased from $157.607M in Q3 2024. |
| Research and Development Expenses (YTD Sep 2025) | $513.120M | Decreased from $628.398M in YTD Sep 2024. |
| Cash and Cash Equivalents (Sep 30, 2025) | $184.847M | Increased from $99.134M at Dec 31, 2024. |
| Notes Payable (Sep 30, 2025) | $268.270M | New liability, zero at Dec 31, 2024, from Note Purchase Agreement. |
| Total Liabilities (Sep 30, 2025) | $426.283M | Increased from $191.671M at Dec 31, 2024. |
| Accumulated Deficit (Sep 30, 2025) | $1,938.981M | Increased from $1,345.714M at Dec 31, 2024, reflecting ongoing losses. |
| Common Shares Outstanding (Nov 6, 2025) | 105,855,155 | Reflects share count as of a recent date. |
| Proceeds from Notes Payable (YTD Sep 2025) | $250.000M | Key financing activity for the period. |
| Fiscal Year | 2024 | Executive compensation data covers this year. |
| Report Date | 2024-03-31 | CONFORMED PERIOD OF REPORT |
| Filing Date | 2024-05-09 | FILED AS OF DATE |
| Quarter Start Date | 2024-01-01 | bhvn:2024 Q1 |
| Previous Year End | 2023-12-31 | bhvn:2023-12-31 |
Frequently Asked Questions
What are the latest SEC filings for Biohaven Ltd. (BHVN)?
Biohaven Ltd. has 43 recent SEC filings from Jan 2024 to May 2026, including 20 8-K, 7 4, 7 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BHVN filings?
Across 43 filings, the sentiment breakdown is: 1 bullish, 41 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Biohaven Ltd. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Biohaven Ltd. (BHVN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Biohaven Ltd.?
Key financial highlights from Biohaven Ltd.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BHVN?
The investment thesis for BHVN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Biohaven Ltd.?
Key executives identified across Biohaven Ltd.'s filings include Michael Thomas Heffernan, Irina Antonijevic, John W. Childs.
What are the main risk factors for Biohaven Ltd. stock?
Of BHVN's 29 assessed filings, 1 were flagged high-risk, 2 medium-risk, and 26 low-risk.
What are recent predictions and forward guidance from Biohaven Ltd.?
Forward guidance and predictions for Biohaven Ltd. are extracted from SEC filings as they are enriched.